Caution is also warranted in buying shares of Arena as after a drug approval, the stock often dips as the buying from initial enthusiasm wanes. A speculative name that may benefit from today's announcement is Athersys …
The stock is on the lower end of the channel with some bullish momentum, VTAE could make investors at this range very happy. Athersys, Inc. (ATHX) quarterly profit came in far ahead of expectations for the fourth …
The stock is up over 90% since the beginning of the year ... Text the word “NASDAQ” to 77948 Athersys, Inc. (Nasdaq: ATHX)is an international biotechnology company engaged in the discovery and development of …
Non-cash expense from stock-based compensation was $0.7 million in both of the 2016 and 2015 third quarters. In the quarter ended September 30, 2016, our operating loss included $0.7 million of a net gain from insurance …
Stem cell developer Athersys (NASDAQ:ATHX) has secured $9 million in a private placement with an unidentified investor. Cleveland-based Athersys said it would issue about 4.3 million shares of common stock and an equal …
Regenerative medicine-focused biotech Athersys, Inc (NASDAQ:ATHX) put some vim into its share price with ... which was way ahead of the $3.72mln tipped by analysts that follow the stock. Shares rose 17% to $2.14 on …
Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report ROCHE HLDG LTD (RHHBY): Free Stock Analysis Report ATHERSYS INC (ATHX): Free Stock Analysis Report EPIZYME INC …
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, …
Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports. Athersys, Inc. (NASDAQ: ATHX) shares gained 9.24 percent to close at $2.01 a …